Dr Margaret Wexler

Breast Cancer UK

Dr Margaret Wexler is head of Science at Breast Cancer UK. She has worked for the charity for the past 6 years. Prior to this she spent 15 years conducting research at the University of East Anglia, Norwich, before working as a lecturer in environmental microbiology and microbial biotechnology. Her research focused on genetic studies in symbiotic nitrogen-fixing bacteria, and more recently, wastewater microbiology, including biological nutrient removal and microbial degradation of contaminants. She has an honours degree in Genetics and Microbiology from the University of Melbourne and a PhD in Environmental Microbiology from the University of Adelaide, Australia.

dont miss

How can we prevent breast cancer?

The seminar will focus on breast cancer prevention and actions that can be taken to reduce breast cancer risk. It will discuss known and suspected risk factors associated with breast cancer development in women, with particular attention given to environmental exposures to endocrine disrupting chemicals.

EVEN MORE SEMINARS

  • Dr James V. Watson, MA., MB., BS., M.Sc., DMRT., FFR., FRCR.: Speaking at the Oncology Convention

    Dr James V. Watson, MA., MB., BS., M.Sc., DMRT., FFR., FRCR.
    MedInfomatics LTD

    Artificial Intelligence – what it is and usage in Medical Records

  • Lucy Thompson ft. Stacie-rae Weir: Speaking at the Oncology Convention

    Lucy Thompson ft. Stacie-rae Weir
    Nipple Innovation Project

    Healing power of permanent realism in restorative tattooing

  • Lucinda Billingham: Speaking at the Oncology Convention

    Lucinda Billingham
    University of Birmingham - Cancer Research Clinical Trials Unit

    National Lung Matrix Trial: testing multiple novel targeted treatments

  • Malcolm Wilson: Speaking at the Oncology Convention

    Malcolm Wilson
    The Colorectal & Peritoneal Oncology Centre, The Christie Hospital NHS Foundation Trust, Manchester

    Cytoreduction and HIPEC in the treatment of peritoneal disease from appendiceal and colorectal tumours

  • Dr. Henrik Harling: Speaking at the Oncology Convention

    Dr. Henrik Harling
    2cureX

    IndiTreat® functional profiling, to match effective cancer drug treatment to individual cancer patients